CCR3 and CCR4 are the members of CC chemokine receptor family expressed on Th2 type CD4 + T cells. In this study, variation screening of the entire coding regions of CCR3 and CCR4 was performed, and possible association with several autoimmune diseases was tested, using the genomic DNA from 304 Japanese healthy individuals and 272 Japanese patients with rheumatic diseases. One non-synonymous substitution was identified in CCR3 gene, whereas in CCR4 gene, two non-synonymous and two synonymous substitutions were detected. Among the synonymous substitutions, CCR4 1014(C→T) was observed in 7.2% of the healthy individuals and 6.6% of the patients, and was considered as a single nucleotide polymorphism. All other variations were observed in only one or two individuals. No significant association was observed between any of the variations and any of the rheumatic diseases. Among these variations, CCR3-C218S substitution coded by 652(T→A) substitution was localized in the region conserved among the G protein coupled receptor family. Reactivity of eosinophils to the monoclonal antibody against CCR3 and the chemotaxis to eotaxin were slightly reduced in this patient as compared with healthy controls or a patient with Behçet disease homozygous for the common allele, while CCR3 mRNA level was not different. These findings suggest that CCR3-C218S substitution may lead to the reduced function of CCR3 at the protein level. Further study will be of interest to test whether CCR3-C218S variation or any of the CCR4 variations has a significant role in rendering susceptibility to immunological diseases or resistance to HIV infection.
Introduction
The chemokines are a family of chemotactic cytokines that mediate a range of pro-inflammatory effects on leukocytes, including chemotaxis, degranulation, and integrin activation. Chemokines are divided into four groups based on the primary sequence of the first two cysteines: the CXC (␣-), CC (␤-), C (␥-), and CX3C (␦-) chemokines. Chemokines act via seven-transmembrane-domain (7TM) receptors, which form a distinct group of structurally related proteins within the superfamily of receptors that signal through heterotrimeric GTP-binding proteins (G proteins) . A number of conserved structural motifs have been found mainly within the transmembrane domains.
expressed on eosinophils but also on basophils, [3] [4] [5] and on a subset of T lymphocytes with a certain type of Th2 helper properties that colocalize with eosinophils on allergic sites, [6] [7] [8] and is believed to be the principal chemokine receptor for the recruitment of these cells. 1, 9, 10 CCR4 is expressed on CD4 + T lymphocytes producing Th2 type cytokines in thymus and peripheral blood, and is considered to play a role in CD4 + T cell homing. 8 Both CCR3 and CCR4 are recognized as specific markers of Th2 subset among the CD4 + T cells. 7, 8, 10 CCR4 binds two chemokines, thymus and activationregulated chemokine (TARC) 11 and macrophage-derived chemokine (MDC). 12 They are lymphocyte specific chemokines and are believed to act specifically on chronically activated Th2 lymphocytes via CCR4. [13] [14] [15] It is remarkable that the pathophysiologically relevant leukocytes share CCR3 expression and can be recruited concomitantly to sites of allergic inflammation by the same set of chemokines. T lymphocytes expressing CCR3 are found to colocalize with eosinophils in atopic dermatitis, nasal polyps and ulcerative colitis, whereas the lymphocytes in non-allergic infiltrates are generally CCR3-negative. 16 CCR3 binds several chemokines. Eotaxin and eotaxin-2 bind only to CCR3 whereas RANTES, monocyte chemotactic protein (MCP)-2, MCP-3, and MCP-4 also bind to other CC-chemokine receptors. 17, 18 In mice with a deletion of the eotaxin gene, allergen-induced eosinophil infiltration into the lungs was retarded, but the defect was compensated at later stages by other chemokines. 17 Thus, a more sustained effect could result from disruption of the gene encoding CCR3.
Another important role of chemokine receptor is to serve as a coreceptor for human immunodeficiency virus (HIV)-1 infection. CCR3 is a coreceptor for some types of pathogenic macrophage (M)-tropic strains, especially neurotropic HIV-1 isolates that are likely to infect the central nervous system and cause the dementia associated with acquired immunodeficiency syndrome (AIDS). [19] [20] [21] [22] [23] In addition, HIV-1-specific lytic activity of cytotoxic T lymphocytes (CTLs) derived from the patients was reported to be enhanced by RANTES, which acts on the CTLs through CCR3. The mechanism involved in such a phenomenon is different from the role of RANTES as a competitor for HIV-1 coreceptor usage. 24 Besides, MDC was reported to have a suppressive activity on HIV-1, which is not dependent on strain tropism, 25 suggesting a role for CCR4 in HIV-1 entry.
Based on such evidence, we hypothesized that genetic variations of CCR3 and CCR4 might be associated with the susceptibility to a range of immunological diseases, especially autoimmune rheumatic diseases in which the imbalance of Th1 and Th2 cells has been implicated. 26, 27 Thus far no attempts have been reported on the screening of gene variations of these receptors. In the present study, we performed a systematic variation screening of human CCR3 and CCR4, and made an attempt to examine the possibility that any of the genetic variation may be associated with the susceptibility to rheumatic diseases.
Results

Identification of new variants of CCR3 and CCR4
Systematic screening of the entire coding regions of CCR3 and CCR4 for gene variations was performed on genomic DNA samples from healthy Japanese individuals and patients, using a polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) method. Representative SSCP pattern is shown in Figure 1 . The nucleotide sequences of the detected variations were determined by direct sequencing.
Using this approach, one novel nucleotide sequence variation was identified in CCR3 ( Figure 1 , Table 1 ). A Tto-A single nucleotide substitution was detected at position 652 (counting from the ATG start codon), which resulted in the non-conservative amino acid change of cysteine at position 218 to serine (CCR3-C218S) within the fifth transmembrane region (TM5) of the CCR3. Similarly, four novel single nucleotide substitutions were detected in CCR4 ( Figure 1 , Table 1 ), two of which resulted in the amino acid substitutions. In addition, we incidentally detected four additional mismatches with the published sequence 28 at nucleotide positions 414(G→A), 417(A→T), 1068(T→C) and 1169(C→T). Because all of the 12 sequenced alleles commonly contained all four substitutions, it is likely that these sequences define the common allele of CCR4 at least in Japanese.
Analysis of association between CCR3 or CCR4 variations and rheumatic diseases
We next examined whether any of the variations of CCR3 or CCR4 is associated with the susceptibility to any of the rheumatic diseases, using case-control association analysis. The results are summarized in Table 1. CCR3-C218S, CCR4-L130V[388(C→G)], CCR4-V166V[498(G→C)] were detected in one sample from a patient with Behçet disease, from a patient with rheumatoid arthritis (RA), and from a healthy individual, respectively. CCR4-C178S[533(G→C)] was detected in one patient with systemic lupus erythematosus (SLE) and one healthy individual. All of these individuals were heterozygous for the common allele and the variant alleles. Thus, these variations could be regarded as relatively rare variants.
On the other hand, CCR4-Y338Y [1014(C→T)] was detected in 22 of 304 healthy individuals (7.2%) and in 18 of 272 patients (6.6%). One patient with RA was homozygous for CCR4-Y338Y. This variation could be considered as a single nucleotide polymorphism (SNP), although no association with any of the tested diseases seemed to be present. Only one patient with RA possessed two of the variations (CCR4-L130V, Y338Y): all other individuals with variations had a base substitution only at a single position. 
a Numbering starts at the ATG translation initiation. AA, amino acid. In addition, four mismatches with the published sequence, 414(G→A), 417(A→T), 1068(T→C), 1169(C→T), were detected in all sequenced alleles. 1169(C→T) was located within 3′-untranslated region, and all other three were synonymous substitutions.
d RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; MCTD, mixed connective tissue disease; AS, ankylosing spondylitis.
Flow-cytometric analysis of cell-surface expression of C218S variant of CCR3
Since CCR3-C218S substitution is located within the TM5 and changes the important conserved motif M(X2)CY, it was considered possible that this variation may have a significant effect on the level of expression or on the conformation of the expressed protein. To test whether the variant has significant alteration in the level of cell-surface expression, flow cytometric analysis using a monoclonal antibody (mAb) to CCR3 was carried out. The reactivity of mAb to peripheral blood eosinophils from one patient with Behçet disease carrying CCR3-C218S substitution was compared with that to eosinophils from healthy individuals and one patient with Behçet disease who were homozygous for the common allele. CD16 was used as the surface marker to exclude neutrophils. The results are shown in Figure 2 . Relative mean fluorescence intensity (relative MFI) of CCR3 was calculated by the mean fluorescence intensity (MFI) of anti-CCR3 staining of CD16-negative polymorphonuclear cells divided by that of control mAb staining. Slight reduction in the fluorescence intensity was observed in the patient with CCR3-C218S substitution (relative MFI = 2.6) compared with the patient without substitution (relative MFI = 4.0) and two healthy individuals without substitution (relative MFI = 4.0).
Chemotaxis analysis of C218S variant of CCR3
We next examined whether CCR3-C218S substitution has a significant effect on the interaction of CCR3 with its specific ligand, eotaxin, using chemotaxis analysis. The results of chemotactic activity of the eosinophils are shown in Table 2 . Chemotactic activity was slightly reduced in the patient with Behçet disease carrying C218S as compared with a patient without C218S (30.5 ± 3.7 vs 52.2 ± 8.9 %, P = 0.088) and a healthy individual not carrying C218S (30.5 ± 3.7 vs 54.0 ± 8.1%, P = 0.059) at the eotaxin concentration of 200 ng/ml, although the difference was of borderline significance. Both patients with Behçet disease were taking low dose colchicine (0.5 g/day); therefore, the difference could not be explained by colchicine. These results suggested that the substitution may lead to a functional abnormality of CCR3. RT-PCR analysis of mRNA expression of C218S variant of CCR3 Reduced reactivity with the monoclonal antibody and lower response to eotaxin of the eosinophils from the heterozygous patient may result from the conformational change of the CCR3 or lower mRNA expression of the CCR3-C218S allele. To test whether the variant has significant alteration in the level of mRNA expression, quantitative RT-PCR analysis using competitor DNA was carried out. The quantity of CCR3 mRNA from eosinophils from the patient with Behçet disease carrying CCR3-C218S substitution was estimated to be 1.8 pg/10 6 cells, and that from the patient without that substitution was 1.6 pg/10 6 cells. These results indicated that the substitution does not lead to reduction in the CCR3 mRNA level.
Discussion
In the present study, we carried out a variation screening of the entire coding regions of human CCR3 and CCR4, and detected a number of new variations. Although evidence of association with rheumatic diseases was not obtained, some of the variations seem to be potentially important in terms of the function of the receptors. Because of the relatively small number of the patients with each disease, the association study described in this paper should be considered as a preliminary one. Large scale case-control studies with age-and sex-matched controls and family-based association studies will be of particular interest in the future.
Human CCR3 gene is located at chromosome 3p21.3.
29
Its product is expressed mainly on eosinophil surface. 4 The newly identified variation, C218S substitution, is located in TM5 region, and changes the conserved motif in the G protein coupled receptor (GPCR) family, M(X2)CY into M(X2)SY. The M(X2)CY motif is considered to play an important role in the construction of the ligand binding pocket, and the change of that motif is likely to influence on ligand affinity. 30, 31 Slightly diminished reactivity to monoclonal antibody and the response to eotaxin in spite of normal level of mRNA in the eosinophils from the heterozygous individual seem to be compatible with the possibility that C218S substitution may result in the conformational change of the ligand binding pocket of the CCR3. It will be of interest to test the effect of this substitution on the response to other CCR3 ligand, such as RANTES, in the future study. CCR3-C218S allele was detected in only one individual with Behçet disease among 304 healthy Japanese individuals and 272 patients, indicating that this is probably a rare variant, at least in Japanese. Since only one of 12 patients with Behçet disease was positive for this allele, it seems unlikely that this mutation is associated with the susceptibility to Behçet disease. However, the accumulation of the T cells producing Th1 cytokine in the inflamed tissues of the patients with Behçet disease 32 suggests the imbalance of Th1/Th2 cells, which might be related to the possible hypofunction of Th2 cells caused by the C218S mutation. Further analysis on a larger number of patients with Behçet disease will be necessary to draw a definite conclusion.
Human CCR4 gene is located at chromosome 3p24. 29 In CCR4 gene, we identified four novel nucleotide sequence variations, two of which result in amino acid substitution. Y338Y [1014(C→T)] substitution was observed in 7.2% of healthy individuals and 6.6% of patients, including one patient with RA who was homozygous for this substitution. This variation can be considered as a SNP. Although significant difference in the allele positivity was not observed between patients and controls in this study, this SNP may potentially be useful for the analysis of susceptibility gene to other diseases, such as atopy or asthma.
In two non-synonymous substitutions, L130V substitution is located in TM3 region close to the DRY motif, and changes the IFF(X2)L(X2)I motif which is conserved in the CCR family. 1 Because the DRY motif is thought to play an important role in coupling G protein ␣ subunit, 30 it is also possible that L130V substitution has a substantial influence on subsequent signal transduction. L130V substitution was observed in one RA patient, who was also heterozygous for Y338Y substitution. Although it is unlikely that this combination is associated with the susceptibility to RA in general, it cannot be excluded that L130V substitution resulted in an abnormality of signal transduction via CCR4 and hypofunction of Th2 cells, leading to the imbalance of Th1/Th2 cells related to RA, in this particular patient.
Another non-synonymous substitution, C178S, located in the second extracellular loop, was observed in one healthy individual and one patient with SLE, both of them were heterozygous for C178S and the common allele. Because it is possible that C178S substitution results in the conformational change, it will be interesting to test the reaction with monoclonal antibodies to CCR4, which are as yet not available.
Another potential significance of CCR3 and CCR4 variants relates to the HIV-1 infection. The important regions of M-tropic HIV-1 gp120 binding to chemokine receptor are considered to be N-terminal and the first extracellular loop in CCR5, 33 but other regions are also suggested to be involved. 9, 34, 35 It is theoretically possible that CCR3-C218S allele might have a protective effect in the infection with HIV-1 that uses CCR3 as a coreceptor, especially neurotropic isolates. Although HIV-1 strain that uses CCR4 as a coreceptor has not been reported, CCR4 specific ligand, MDC, was reported to have an anti-HIV-1 effect. 25 Because MDC is considered to perform its anti-HIV-1 activity via CCR4, the newly identified variants in this study might have a role in the infection with HIV-1 or in the progression of AIDS.
In conclusion, new variants of CCR3 and CCR4 genes were detected in the Japanese population. Such information will be important in future studies on the possible involvement of CCR3 and CCR4 in immunological diseases including atopy, and in HIV-1 infection.
Materials and methods
Patients and healthy individuals
A total of 304 healthy individuals and 272 patients with rheumatic diseases were examined. The patient group consisted of 145 patients with RA, 66 patients with SLE, 13 patients with dermatomyositis/polymyositis, 12 patients with scleroderma, 12 patients with Behçet disease, 12 patients with Sjö gren syndrome, seven patients with mixed connective tissue disease (MCTD), and five patients with ankylosing spondylitis (AS). These diseases were diagnosed according to the generally accepted criteria. [36] [37] [38] All healthy individuals and patients were unrelated Japanese living in the Tokyo area. The central part of Japan has been shown to be homogeneous with respect to the genetic background, 39 permitting the case-control approach employed in this study. Healthy individuals consisted of the researchers, laboratory workers and students at the institutions where this study was carried out.
Genomic DNA
Genomic DNA from patients and healthy individuals was purified from peripheral blood leukocytes using a commercial kit (QIAamp blood kit, QIAGEN, Hilden, Germany).
PCR-single-strand conformation polymorphism (PCR-SSCP)
The primers used for PCR and the annealing temperature are shown in Table 3 . These primers were designed according to the genomic DNA sequence of CCR3, 4 and the cDNA sequence of CCR4.
28 CCR3 is a single exon gene with the coding region of 1068 bp, and CCR4 is thought to be intronless at least within the coding region of 1083 bp [see reference 40, unpublished observations]. 40 The CCR3 coding region was divided into seven overlapping segments and the CCR4 coding region into six segments of 250-300 bp, because the size of the fragment optimal for SSCP was determined to be 200-400 bp in the previous studies 41 (Table 3) . PCR was carried out using commercially available reagents (GeneAmp and AmpliTaq Gold, Perkin-Elmer, Norwalk, CT, USA). To activate DNA polymerase, preheating was performed for 10 min at 96°C. The amplification conditions consisted of 35 cycles of denaturation for 30 s at 96°C, annealing for 30 s at the temperature shown in Table 3 , and extension for 1 min at 72°C, in a thermal cycler (Thermal cycler MP, Takara, Kyoto, Japan).
The amplified DNA was analyzed using SSCP. The SSCP analysis was performed essentially according to the method described previously. 42 One microliter of solution containing the PCR product was mixed with 7 l of denaturing solution (95% formamide, 20 mm EDTA, 0.05% bromphenol blue, 0.05% xylene cyanol FF). The mixtures were denatured at 96°C for 5 min and immediately cooled on ice. Five microliters of the mixtures were applied to 10% polyacrylamide gel (acrylamide: bis = 49:1). Five percent glycerol were included in the gel for the analyses of several fragments (Table 3) . Electrophoresis was carried out in 0.5 × TBE (45 mm Tris-borate [pH 8.0], 1 mm EDTA) under constant electric current , using a minigel electrophoresis apparatus with a constant temperature control system (AE-6410 and AE-6370; ATTO, Tokyo, Japan). The optimal temperature and the duration of electrophoresis were determined by preliminary experiments (Table 3) . Single-strand DNA fragments in the gel were visualized by a staining dye (SYBR Gold, Molecular Probes, Inc, Eugene, OR, USA).
Direct sequencing PCR products were amplified and both sense and antisense strands were directly sequenced using the same primers as those for the SSCP analysis. Fluorescencebased automated cycle sequencing of PCR products was performed on an automated sequencer (ABI PRISM™ 377 DNA Sequencing System, Perkin-Elmer Applied Biosystems, Foster City, CA, USA), using dye-terminator method according to the manufacturer's instructions (ABI PRISM™ dRhodamine Terminator Cycle Sequencing-Ready Reaction Kit).
Flow-cytometric analysis of CCR3 expression on eosinophils
Fluorescein isothiocyanate (FITC)-mouse IgG1, phycoerythin (PE)-mouse IgG1 and PE-anti-CD16 Ab were purchased from Beckman Coulter, Inc (Fullerton, CA, USA). The monoclonal antibody against human CCR3 (clone No. 444) was generated from CCR3(+) transfectant immunized mouse as previously described. 43 FITC labeled anti-CCR3 Ab (clone No. 444) was prepared by conjugation of purified Ab with FITC (Sigma Chemical Co, St Louis, MO, USA).
Flow-cytometric analysis of CCR3 expression on eosinophils was performed with whole-blood immunostaining as described previously. 44 Briefly, 50 l of wholeblood were diluted with the same volume of PBS. The leukocytes were stained with FITC-anti-CCR3 Ab and PE-anti-CD16 Ab at 4°C for 30 min. Erythrocytes were lysed by treatment with 10 mm potassium bicarbonate containing 0.155 mm ammonium chloride and 0.1 mm EDTA. To analyze the eosinophils within the wholeblood, total granulocytes were gated based on forward and side scatters on FACScan (Becton Dickinson, Mountain View, CA, USA). The CCR3 expression was analyzed in the CD16-negative population of the gated cells. The majority of the CD16-negative population of the gated cells was considered to be eosinophils, and the remainder to be basophils.
Chemotaxis analysis of CCR3 chemoattractant to eosinophils
Eosinophil chemotaxis assay was performed as described previously. 5 In brief, eosinophils were partially purified using dextran sedimentation, density centrifugation with Percoll (1.088 g/ml, Pharmacia, Uppsala, Sweden), and hypotonic lysis of contaminating erythrocytes, as previously described. 45 The migration assay was performed using an assembly consisting of a 96-well chamber (Neuro Probe) and a polycarbonate filter membrane with a pore diameter of 5 m (Nucleopore, Pleasanton, CA, USA). Samples to be tested were transferred to each well of a flat-bottom 96-well plate, and a cell suspension which contained 1-2 × 10 4 Percoll-separated eosinophils was introduced into the top compartment. The chamber CCR3-1  CCR3A1  5′-ACTGGTGTGTTTTACGGAGG-3′  5′ UTR  252 bp  15°C  CCR3B1  5′-GATCATCACCACCACCACAT-3′  TM1  CCR3-2  CCR3A2  5′-ACTCCCTGGTGTTCACTGTG-3′  TM1  237 bp  10°C(+)  CCR3B2  5′-CGCTGTACAAGCCTGTGTGA-3′  TM3  CCR3-3  CCR3A3  5′CTTCCTCGTCACCCTTCCAT-3′  TM2  253 bp  15°C  CCR3B3  5′-AAGAGCTGCTAGCACTGCCA-3′  TM4  CCR3- 18°C  CCR4B1  5′-CATCAGTCATGGACCTGAGC-3′  CY 1st loop  CCR4-2  CCR4A2  5′-AGCCTTGCACCAAAGAAGGC-3′  N terminal  280 bp  12°C  CCR4B2  5′-CCCACCAAGTACATCCAGGA-3′  TM3  CCR4-3  CCR4A3  5′-ACTATGCAGCAGACCAGTGG-3′  TM2  302 bp  6°C  CCR4B3  5′-CGTCGTGGAGTTGAGAGAGT-3′  EC 2nd loop  CCR4-4  CCR4A4  5′-CCTGGCTTTCTGTTCAGCAC-3′  TM4  293 bp  8°C  CCR4B4  5′-ACCAGGGTCTCTAGGAAGAG-3′  TM6  CCR4-5  CCR4A5  5′-GTGGTCCTCTTCCTTGGGTT-3′  TM6  299 bp  12°C  CCR4B5  5′-GGACTGCGTGTAAGATGAGC-3′  C terminal  CCR4-6  CCR4A6  5′-GTGCTCTGCCAATACTGTGG-3′  C terminal  291 was incubated at 37°C, 5% CO 2 for 90 min. The plate was centrifuged to detach the cells from the lower surface of the filter. To determine the number of migrated eosinophils, the cell-associated eosinophil peroxidase content in the lower wells was determined by using o-phenylene diamine as the substrate. The numbers of migrated eosinophils were calculated based on a calibration curve established with varying known numbers of eosinophils.
RT-PCR analysis of CCR3 mRNA expression on eosinophils Total RNA was extracted with a SNAP Total RNA Isolation Kit (Invitrogen, NV Leek, The Netherlands) according to the manufacturer's instructions except that deoxyribonuclease purchased from Nippon Gene (Osaka, Japan) was used. After precipitation with ethanol, the first-strand cDNA was reverse transcribed as described previously. 46 The second-strand DNA synthesis and hotstart amplification were performed using a thermal cycler (Thermal cycler MP, Takara, Kyoto, Japan).
Amplification of cDNA was performed as previously described 46 except that AmpliTaq Gold DNA polymerase (Perkin-Elmer, Branchburg, NJ, USA) was used. Direct and reverse oligo primers for CCR3 (5′-ATCCTACTAT GATGACGTGGGC-3′; position TM1 for sense and 5′-GGCCAGGTACCTGTCGATTG-3′; position TM3 for antisense) were constructed based on the published sequences of mRNA. To activate DNA polymerase, preheating (9 min at 95°C) was performed. Then amplification was performed for 30 cycles of denaturation (30 s at 94°C), annealing (30 s at 62°C), extension (30 s at 72°C) and final extension (10 min at 72°C). PCR products were electrophoresed on a 2% agarose gel and visualized with ethidium bromide. To identify the PCR products as human CCR3, cDNA from L1.2 cells which was transfected with full-length human CCR3 DNA was amplified simultaneously.
The procedures for competitive PCR of CCR3 mRNA were basically the same as those described previously. 46 Briefly, cDNA and varying amounts of competitor cDNA were used as templates, and quantification of the amplified PCR products was performed by ELISA. 47 The amplified products were immobilized on carboxylated-surface plates. The covalently-bound single-strand DNAs were hybridized with digoxigenin-labeled oligonucleotide probes (5′-GTCACCCTTCCATTCTGGATCC-3′ for CCR3 and 5′-AAGTACCGTCGACGTCGGA-3′ for competitor). Hybridized probes were detected with peroxidase-conjugated anti-digoxigenin antibodies, and signals were visualized with tetramethyl benzidine. Because the ratio of the target and competitor templates remained constant during amplification, the quantity of competitor DNA in the PCR templates which yielded an equal amount of the two PCR products was considered to indicate the initial amount of the target gene.
Statistical analysis
Fisher's exact test was used to analyze the significance of the difference in the frequencies of CCR4 genotypes between patients and healthy individuals. Results from the chemotaxis assay were compared using Student's unpaired t-test.
